导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.93% | 2041/4773 |
| 近一周 | -1.88% | 489/5462 |
| 近一月 | -1.04% | 898/5421 |
| 近一季 | -4.45% | 1635/5209 |
| 近半年 | -8.22% | 3588/4920 |
| 近一年 | 4.65% | 1831/4366 |
| 近两年 | 29.46% | 2311/2954 |
| 近三年 | 20.48% | 1454/2253 |
| 成立以来 | 87.96% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.36% 741/4961 |
1.47% 3018/5312 |
- - |
- - |
| 2025 | 6.76% 2947/4813 |
-4.30% 3159/3635 |
1.08% 2475/4076 |
6.99% 3485/4524 |
3.16% 731/4813 |
| 2024 | 18.94% 569/3463 |
9.25% 139/2808 |
1.92% 427/3014 |
7.14% 2823/3129 |
-0.31% 1378/3463 |
| 2023 | 7.40% 145/2656 |
15.79% 205/2280 |
1.35% 219/2385 |
-3.25% 879/2515 |
-5.41% 1349/2655 |
| 2022 | -12.39% 281/2207 |
-10.55% 402/1919 |
2.45% 1301/2016 |
-9.35% 272/2113 |
5.47% 464/2208 |
| 2021 | 24.78% 117/1822 |
2.44% 219/1255 |
3.58% 966/1330 |
17.28% 65/1466 |
0.26% 1149/1822 |
| 2020 | 11.57% 824/1250 |
-7.18% 528/1028 |
0.80% 997/1067 |
8.84% 697/1164 |
9.56% 632/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时央创ETF联接A VS. 长安沪深300非周期A(740101) |